Design Therapeutics Files 8-K

Ticker: DSGN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1807120

Design Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyDesign Therapeutics, Inc. (DSGN)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, filing

TL;DR

Design Therapeutics filed an 8-K, likely with financial updates. Check for details.

AI Summary

On January 13, 2025, Design Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of financial statements and exhibits, and a Regulation FD disclosure. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing indicates Design Therapeutics, Inc. is providing required disclosures to the SEC, which may include important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications mentioned in the excerpt.

Key Players & Entities

  • Design Therapeutics, Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of earliest event reported
  • 001-40288 (company) — SEC File Number
  • 823929248 (company) — IRS Employer Identification No.
  • 6005 Hidden Valley Road Suite 110 (company) — Principal Executive Offices Address
  • Carlsbad, California (company) — Principal Executive Offices Location
  • 92011 (company) — Principal Executive Offices Zip Code
  • (858) 293-4900 (company) — Registrant's Telephone Number

FAQ

What is the primary purpose of this 8-K filing by Design Therapeutics, Inc.?

The filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically for Regulation FD Disclosure and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The date of the earliest event reported is January 13, 2025.

What is the SEC File Number for Design Therapeutics, Inc.?

The SEC File Number for Design Therapeutics, Inc. is 001-40288.

Where are Design Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 6005 Hidden Valley Road, Suite 110, Carlsbad, California, 92011.

What is the IRS Employer Identification Number for Design Therapeutics, Inc.?

The IRS Employer Identification Number for Design Therapeutics, Inc. is 823929248.

Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-13 09:09:12

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share DSGN Nasdaq Glo

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Design Therapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information under this Item 7.01 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Company Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Design Therapeutics, Inc. Date: January 13, 2025 By: /s/ Pratik Shah, Ph.D. Pratik Shah, Ph.D. President, Chief Executive Officer and Chairperson

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.